Mesoblast Ltd
Change company Symbol lookup
Select an option...
MESO Mesoblast Ltd
DPW DPW Holdings Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Based in Australia
Company profile

Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$9.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
73

10-day average volume:
1,872,815
73
  • Prev Close
    9.72
  • Today's Open
    --
  • Day's Range
    --
  • Avg Vol (10-day)
    1.9M
  • Last (time)
    3:59p ET 01/15/21
  • Last (size)
    22
  • 52-Wk Range
    3.12 - 21.28
    LowHigh
  • (03/23/20 - 08/17/20)
    211.53%
  • 160.4%
  • Market Cap
    1.1B
  • Shares Outstanding
    117.5M
  • -0.89
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 3.7
  • 2.21
  • (% of float 12/31/20)
    3.40

Latest News

January 11, 2021
5:10 pm ET
Globe Newswire
January 10, 2021
11:25 pm ET
Globe Newswire
December 17, 2020
10:07 pm ET
Globe Newswire
6:31 pm ET
Globe Newswire
December 14, 2020
5:27 pm ET
Globe Newswire
4:55 pm ET
Globe Newswire
December 07, 2020
4:34 pm ET
Newsfile
1:31 pm ET
Accesswire
10:14 am ET
Newsfile
10:07 am ET
Newsfile
10:00 am ET
Globe Newswire
8:45 am ET
Newsfile
6:20 am ET
Accesswire
6:00 am ET
Globe Newswire
December 05, 2020
6:32 pm ET
PR Newswire
7:45 am ET
BusinessWire
December 04, 2020
6:00 pm ET
BusinessWire
12:16 pm ET
Accesswire
9:42 am ET
Newsfile
9:31 am ET
Accesswire
8:00 am ET
Globe Newswire
8:00 am ET
BusinessWire
December 03, 2020
7:13 pm ET
Accesswire
6:45 pm ET
Globe Newswire
2:15 pm ET
Accesswire
11:05 am ET
Accesswire
9:34 am ET
Newsfile
December 02, 2020
11:25 am ET
Newsfile
11:00 am ET
Newsfile
9:39 am ET
Newsfile
6:00 am ET
Globe Newswire
December 01, 2020
9:50 pm ET
Accesswire
9:00 pm ET
Globe Newswire
6:37 pm ET
Accesswire
5:56 pm ET
Newsfile
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.